Zuoli Pharmaceutical announced that revenue for the first half of 2026 was 1,764 billion yuan, up 10.30% year on year; net profit attributable to shareholders of listed companies was 375 million yuan, up 0.38% year on year; net profit after deducting non-recurring profit and loss was 374 million yuan, up 0.53% year on year. The company plans to pay a cash dividend of 3.5 yuan for every 10 shares without using the Provident Fund to increase share capital; the issuance of convertible corporate bonds to unspecified targets was reviewed and approved by the Shenzhen Stock Exchange Listing Review Committee on August 21, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.